Format

Send to:

Choose Destination
See comment in PubMed Commons below
Rev Med Suisse. 2006 Mar 15;2(57):738-40, 743-5.

[Infectious risks of immunomodulating therapies in rheumatology].

[Article in French]

Author information

  • 1Service des maladies infectieuses, Département de médecine, HUG, 1211 Genève 14. Christian.vandelden@hcuge.ch

Abstract

Corticosteroids and cytotoxic drugs form the conventional immunomodulators in rheumatology. This therapeutic arsenal has recently been widened by TNF-alpha antagonists and other anti-cytokines. If rheumatoid arthritis is itself associated with infections, immunomodulating therapies further increase the risk of infection, especially when used in combination therapies. Among conventional therapies, corticosteroids are associated with the highest risk for both common bacterial and opportunistic infections. Infliximab is the TNF-alpha antagonist associated with the highest risk of infection. Its use has been particularly associated with cases of severe tuberculosis. All patients at risk for tuberculosis, treated with corticosteroids or TNF-alpha antagonists, should therefore receive an adequate prophylaxis.

PMID:
16604876
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk